Clifford Samuel

Clifford Samuel is a Board Director at Antiva Biosciences with over 25 years of commercial experience in the biopharmaceutical industry, and more than two decades at Gilead Sciences Inc. in leadership roles across sales, managed markets, and global commercial operations. He joined Gilead Sciences Inc. in 1996 as a member of the company’s commercial organization, newly established at the time, to support the introduction of Gilead’s first commercial product. Samuel oversaw the ongoing development and implementation of innovative manufacturing, distribution, and business models to make the company’s HIV, viral hepatitis, and fungal medicines available at affordable prices in resource-limited and evolving economies. In addition to coordinating Gilead’s internal operations in these markets, Samuel builds strategic partnerships around the world, including collaborations with governments, non-governmental organizations, and generic drug manufacturers to ensure that large-scale access to medicines is achieved. Under his leadership, Gilead has entered into generic licensing agreements with 19 companies in China, India, and South Africa, creating a competitive market for generic HIV and hepatitis B drugs that has dramatically reduced prices and helped to deliver medicines to more than 18 million people in need.